About

Healthy and Happy Patients

OUR MISSION

Cogentis discovers and develops first-in-class therapeutics that prevent neurodegeneration and restore brain function to benefit the lives of those patients and their families.

OUR VISION

Our vision is to lead the world in providing disease-modifying treatments capable of halting or reversing neurodegenerative conditions such as frontotemporal dementia (FTD), Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease (AD).

About Our Clinic

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Excepteur sint occaecat cupidatat non proident, sunt in culpa ciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

We Are Always

Glad to Help

Elit sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation.

Daniel Hanson

Cogentis Team

KENT WERNER M.D. , PH.D.

Founder and CEO

Dr. J. Kent Werner, Jr. is a board-certified neurologist and neuroscientist. He completed his medical degree, cellular and molecular neuroscience doctorate, and neurology residency at Johns Hopkins University. Dr. Werner studied under the mentorship of Dr. Solomon Snyder in the Department of Neuroscience. He serves currently as Adjunct Assistant Professor in the Department of Neurology. He holds an Associate Professor appointment in the Department of Neurology at the Uniformed Services University. Dr. Werner has won over $10M in funding from federal and foundational sources and has over 30 publications in the field of neuroscience.

ALBERT HUNT JR PH.D., MBA

Director of Scientific and Business Operations

Dr. Albert Hunt, Jr. joined Cogentis with a Ph.D. in Biomedical Sciences/Neuroscience and his MBA. Through his doctoral and postdoctoral research, Dr. Hunt’s areas of expertise include neurodegenerative diseases including Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. Using his expertise in chemistry and neuroscience, Dr. Hunt is working to develop next-generation therapies for neurodegeneration and diseases of aging.

Henry Kay

Business Advisor

Henry Kay is currently serving on the boards of directors of several Life Science companies in the US and Canada. He is an active Angel Investor involved with Boston Harbor Angels and Sky Venture Group.

Greg erman

Business Advisor

Greg Erman is President & CEO of EmpiraMed, Inc.. He sits on several biotech and digital health corporate boards of directors, is an angel investor, and is a part-time paid entrepreneurship lecturer at Harvard Medical School. Greg’s career centers on entrepreneurship, intellectual property research commercialization, and business leadership.

Advisors

YVONNE ANGEL PH.D.

Director of Peptide Chemistry Chempartner

Yvonne has over 16 years of experience in the pharmaceutical industry. She has led research teams at Eli Lilly, Wyeth, Affymax, Ipsen Bioscience and is currently working on consulting projects through her own consulting firm, Picotide Technologies. Her primary expertise is in design, synthesis and lead optimization of novel peptides, peptidomimetics and peptide conjugates. Yvonne received her PhD in Medicinal Chemistry at the University of Wisconsin-Madison and post-doctoral work at the University of Minnesota.

AJAY VERMA M.D. , PH.D.

Senior Vice President Codiak Biosciences

Ajay has over a decade of experience leading teams in the pharmaceutical industry at Novartis, Biogen, United Neuroscience, and most recently Codiak Biosciences. He bring deep expertise in clinical trial design and execution as well as in drug development in the CNS space. While at Biogen, he previously oversaw the development of Aducanumab though phase 2 development.

SANJEEV THOHAN PH.D.

Director of Preclinical Safety Xeris Pharmaceuticals

Sanjeev has overseen the development of over 30 drugs through IND filing with the FDA where he was most recently at Novartis. He is an expert in toxicology and safety and is currently the Director of Safety and Toxicology at Xeris Pharmaceuticals.

EREZ EITAN PH.D. , M.B.A.

Chief Scientific Officer NeuroDex

Dr. Eitan was the first to study exosomes at the National Institute on Aging (NIA). As a pioneer in the field, Dr. Eitan has developed novel methodologies and published over 27 peer reviewed articles. During his recent tenure as senior scientist in a leading diagnostic company, Dr. Eitan has led research collaborations with several pharmaceutical companies. He currently leading the science at NeuroDex who is collaborating with us to develop a companion diagnostic for CT526.

michael alijhanian

Ph.D. Chief Scientific Officer Pinteon

Dr. Ahlijanian is a recognized leader in the development of novel therapeutics for central nervous system diseases and accomplished in promoting cultural change in research organizations. Prior to his role at Pinteon, he was the director of genetically defined disease biology and head of clinical biomarkers at Bristol-Myers Squibb. In this role, he led scientific discovery teams that produced clinical candidates for large and small molecule therapeutics for neurologic and muscle-wasting diseases. Dr. Ahlijanian held previous senior management roles as head of neuroscience at FORMA Therapeutics, vice president of research at EnVivo Pharmaceuticals and executive director of neuroscience operations at Pfizer. He currently serves on the Independent Review Committee at Target ALS and on the ADDF Scientific Review Committee.

Harish C. Pant

Ph.D. Scientist Emeritus Laboratory of Neurochemistry, NINDS

Dr. Pant received his M.A. and Ph.D. degrees in Physics from Agra University, Agra, India. His postdoctoral studies were conducted on the mechanisms of electron and ion transport in model membrane systems at the Department of Biophysics at Michigan State University. He joined the Laboratory of Neurobiology in the NIMH as a senior staff fellow in 1974 with Dr. Ichiji Tasaki where he studied the function of the axonal cytoskeleton in the squid giant axon. In 1979 he moved to the NIAAA extending his studies on the neuronal cytoskeleton and the effects of alcohol on its regulation. Dr. Pant moved to the NINDS in 1987 and retired in 2019 as Chief of the Neuronal Cytoskeletal Protein Regulation Section and was appointed a Scientist Emeritus. His research focused on studying the mechanisms of topographic regulation of neuronal cytoskeleton proteins by post-translational modification, including the role of kinase cascades in the normal brain and during neurodegeneration.